Cartesian Therapeutics (RNAC) Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Current Assets data on file, last reported at $122.0 million in Q1 2026.

• On a quarterly basis, Current Assets fell 34.08% year-over-year to $122.0 million in Q1 2026; TTM through Mar 2026 was $122.0 million, a 34.08% decrease from a year earlier, with the FY2025 full-year figure at $129.3 million, down 40.32% from the prior year.
• Current Assets for Q1 2026 stood at $122.0 million, down from $129.3 million in the prior quarter.
• Over the last five years, Current Assets for RNAC reached as high as $229.1 million in Q3 2024 and fell as low as $89.9 million in Q3 2023.
• Historically, Current Assets has averaged $145.9 million across 5 years, with a median of $138.4 million in 2023.
• Across the five-year window, Current Assets tumbled 43.72% in 2023 and surged 154.97% in 2024, its largest moves.
• Year by year, Current Assets stood at $148.1 million in 2022, then plunged by 38.75% to $90.7 million in 2023, then jumped by 138.76% to $216.6 million in 2024, then slumped by 40.32% to $129.3 million in 2025, then slipped by 5.6% to $122.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $122.0 million in Q1 2026, $129.3 million in Q4 2025, and $147.3 million in Q3 2025.